IMUNON INC (IMNN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:IMNN • US15117N7012

3.27 USD
+0.2 (+6.51%)
Last: Feb 6, 2026, 04:10 PM
Fundamental Rating

2

IMNN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. IMNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMNN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • IMNN had negative earnings in the past year.
  • In the past year IMNN has reported a negative cash flow from operations.
  • In the past 5 years IMNN always reported negative net income.
  • In the past 5 years IMNN always reported negative operating cash flow.
IMNN Yearly Net Income VS EBIT VS OCF VS FCFIMNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • IMNN has a worse Return On Assets (-159.43%) than 85.69% of its industry peers.
  • The Return On Equity of IMNN (-351.06%) is worse than 73.28% of its industry peers.
Industry RankSector Rank
ROA -159.43%
ROE -351.06%
ROIC N/A
ROA(3y)-122.06%
ROA(5y)-90.29%
ROE(3y)-238.61%
ROE(5y)-173.69%
ROIC(3y)N/A
ROIC(5y)N/A
IMNN Yearly ROA, ROE, ROICIMNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMNN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNN Yearly Profit, Operating, Gross MarginsIMNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, IMNN has more shares outstanding
  • IMNN has more shares outstanding than it did 5 years ago.
  • IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNN Yearly Shares OutstandingIMNN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
IMNN Yearly Total Debt VS Total AssetsIMNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -68.74, we must say that IMNN is in the distress zone and has some risk of bankruptcy.
  • IMNN has a Altman-Z score of -68.74. This is amonst the worse of the industry: IMNN underperforms 92.18% of its industry peers.
  • IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -68.74
ROIC/WACCN/A
WACCN/A
IMNN Yearly LT Debt VS Equity VS FCFIMNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 1.73 indicates that IMNN should not have too much problems paying its short term obligations.
  • The Current ratio of IMNN (1.73) is worse than 78.24% of its industry peers.
  • A Quick Ratio of 1.73 indicates that IMNN should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.73, IMNN is not doing good in the industry: 77.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
IMNN Yearly Current Assets VS Current LiabilitesIMNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.38% over the past year.
EPS 1Y (TTM)54.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMNN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.89% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.78%
EPS Next 2Y36.29%
EPS Next 3Y23.07%
EPS Next 5Y15.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMNN Yearly Revenue VS EstimatesIMNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
IMNN Yearly EPS VS EstimatesIMNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1K -2K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • IMNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNN Price Earnings VS Forward Price EarningsIMNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNN Per share dataIMNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMNN's earnings are expected to grow with 23.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.29%
EPS Next 3Y23.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMNN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMUNON INC

NASDAQ:IMNN (2/6/2026, 4:10:05 PM)

3.27

+0.2 (+6.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)02-25
Inst Owners5.13%
Inst Owner Change2.89%
Ins Owners0.79%
Ins Owner Change2.34%
Market Cap10.04M
Revenue(TTM)N/A
Net Income(TTM)-14.33M
Analysts80
Price Target65.18 (1893.27%)
Short Float %8.29%
Short Ratio4.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.27%
Min EPS beat(2)37%
Max EPS beat(2)55.53%
EPS beat(4)4
Avg EPS beat(4)29.86%
Min EPS beat(4)5.34%
Max EPS beat(4)55.53%
EPS beat(8)7
Avg EPS beat(8)16.16%
EPS beat(12)9
Avg EPS beat(12)8.61%
EPS beat(16)10
Avg EPS beat(16)-15.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.89%
PT rev (3m)-22.89%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)-28.54%
EPS NY rev (1m)-10.37%
EPS NY rev (3m)-26.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)-11.25
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)-4.87
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS0
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -159.43%
ROE -351.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-122.06%
ROA(5y)-90.29%
ROE(3y)-238.61%
ROE(5y)-173.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 114.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -68.74
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)77.1%
Cap/Depr(5y)55.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.84%
EPS Next Y73.78%
EPS Next 2Y36.29%
EPS Next 3Y23.07%
EPS Next 5Y15.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.82%
OCF growth 3YN/A
OCF growth 5YN/A

IMUNON INC / IMNN FAQ

Can you provide the ChartMill fundamental rating for IMUNON INC?

ChartMill assigns a fundamental rating of 2 / 10 to IMNN.


What is the valuation status for IMNN stock?

ChartMill assigns a valuation rating of 1 / 10 to IMUNON INC (IMNN). This can be considered as Overvalued.


How profitable is IMUNON INC (IMNN) stock?

IMUNON INC (IMNN) has a profitability rating of 0 / 10.